PROC Procaps Group S.A.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
1.96
PEG
0.00
P/B
-108.52
P/S
0.25
EV/EBITDA
3.62
DCF Value
$10.21
FCF Yield
-17.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
58.4%
Operating Margin
12.8%
Net Margin
10.4%
ROE
-221.9%
ROA
9.2%
ROIC
12.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 null | $118.4M | $8.2M | $— |
| Q2 null | $110.1M | $27.0M | $— |
| Q1 null | $84.2M | $6.6M | $— |
| Q4 null | $101.5M | $10.4M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
LU
Exchange
—
Beta
0.17
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.